Abemaciclib
- Generic Name
- Abemaciclib
- Brand Names
- Verzenio, Verzenios
- Drug Type
- Small Molecule
- Chemical Formula
- C27H32F2N8
- CAS Number
- 1231929-97-7
- Unique Ingredient Identifier
- 60UAB198HK
- Background
Abemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity. On September 28, 2017, FDA granted approval of abemaciclib treatment under the market name Verzenio for the treatment of HR-positive and HER2-negative a...
- Indication
适应症为:⑴单药治疗接受过内分泌疗法和化疗后疾病进展的 ER+/HER2-晚期或转移性乳腺癌；⑵或联合氟维司群，二线治疗接受过内分泌疗法后疾病进展的 ER+/HER2-晚期或转移性乳腺癌；⑶联合芳香酶抑制剂作为 ER+/HER2-绝经后女性晚期或转移性乳腺癌的初始内分泌疗法。
- Associated Conditions
- HR+, HER2-, Advanced Breast Cancer, Early Hormone Receptor Positive, HER2/Neu Negative Node Positive Breast Cancer, Metastatic HR + HER2 - breast cancer
- Associated Therapies
- -
First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2023-03-08
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- Relay Therapeutics, Inc.
- Target Recruit Count
- 265
- Registration Number
- NCT05759949
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Community Cancer Center North, Indianapolis, Indiana, United States
🇺🇸Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States
A Study of Ruxolitinib in Combination With Abemaciclib for the Treatment of Myelofibrosis
- Conditions
- Interventions
- First Posted Date
- 2023-02-06
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 18
- Registration Number
- NCT05714072
- Locations
- 🇺🇸
Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States
A PoC Study to Evaluate Treatments' Efficacy by Monitoring MRD Using ctDNA in HR-positive/HER2-negative EBC Population
- Conditions
- Interventions
- First Posted Date
- 2023-02-01
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- MedSIR
- Target Recruit Count
- 1260
- Registration Number
- NCT05708235
- Locations
- 🇪🇸
Clínica Universidad de Navarra, Madrid, Spain
🇪🇸Hospital Universitario Arnau de Vilanova de Lleida, Lleida, Spain
🇪🇸Hospital Universitario de Torrejón, Madrid, Spain
Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-11-16
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Praful Ravi, MB BCHir, MRCP
- Target Recruit Count
- 9
- Registration Number
- NCT05617885
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
VS-6766+Abema+Fulv in Met HR+/HER- BC
- Conditions
- Interventions
- First Posted Date
- 2022-11-08
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- Adrienne G. Waks
- Target Recruit Count
- 63
- Registration Number
- NCT05608252
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institite, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-10-03
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Stemline Therapeutics, Inc.
- Target Recruit Count
- 400
- Registration Number
- NCT05563220
- Locations
- 🇩🇪
Universitaetsklinikum Mannheim, Mannheim, Baden-Wuerttemberg, Germany
🇺🇸Dothan Hematology and Oncology, Dothan, Alabama, United States
🇺🇸Mayo Clinic - Arizona, Phoenix, Arizona, United States
TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A)
- First Posted Date
- 2022-09-21
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 37
- Registration Number
- NCT05548127
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸Moffitt McKinley Hospital, Tampa, Florida, United States
🇺🇸Stanford Women's Cancer Center, Palo Alto, California, United States
Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-09-01
- Last Posted Date
- 2024-06-07
- Lead Sponsor
- University of California, Irvine
- Target Recruit Count
- 20
- Registration Number
- NCT05524584
- Locations
- 🇺🇸
Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange, California, United States
ETHAN - ET for Male BC
- First Posted Date
- 2022-08-15
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Jose Pablo Leone
- Target Recruit Count
- 60
- Registration Number
- NCT05501704
- Locations
- 🇺🇸
Georgetown University Medical Center, Washington, District of Columbia, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
Chidamide in Combination With Abemaciclib and Endocrinotherapy（Doctor's Choice） in Breast Cancer Patients Previously Treated With Palbociclib
- Conditions
- Interventions
- First Posted Date
- 2022-07-19
- Last Posted Date
- 2024-01-22
- Lead Sponsor
- Biyun Wang, MD
- Target Recruit Count
- 44
- Registration Number
- NCT05464173
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.